Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo

 
• By Ian Schofield

The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.

Tooth wheel mechanism with DIFFERENT, SIMILAR letters
Sandoz is having another crack at getting its biosimilar pegfilgrastim approved

More from Biosimilars

More from Biosimilars & Generics